Therapies targeting IL-17, TNF, and MAPK have been discussed for COVID-19 treatment [25, 78–81].Taken together, our finding of correlations between thrombocytosis (platelet count) and molecules involved in cell adhesion, IL-17, TNF, MAPK signaling pathways imply a coordinated effort of these pathways toward thrombocytosis-mediated coagulopathy during ARDS. The gene discussed is TNF; the disease is thrombocytosis disease.